文献速递头颈与中枢神经肿瘤

KRAS变异与头颈部鳞状细胞癌西妥昔单抗反应:一项随机临床试验的二次分析

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2017-01-01

基于3期试验NRG Oncology RTOG 0522的891例晚期头颈部鳞状细胞癌患者,413例可检测KRAS变异。KRAS变异患者(16.9%)接受西妥昔单抗后第一年无进展生存期和1至2年总生存期改善。KRAS变异与p16状态对总生存期存在显著三重交互作用,且KRAS变异患者血浆TGF-β1水平显著升高。

要点

  • KRAS变异患者接受西妥昔单抗后第一年PFS的HR为0.31(95%CI 0.10-0.94,P=.04)。
  • KRAS变异患者接受西妥昔单抗后1至2年OS的HR为0.19(95%CI 0.04-0.86,P=.03)。
  • KRAS变异患者血浆TGF-β1中位水平显著升高(23376.49 vs 18476.52 pg/mL,P=.03)。

核心结论

  • KRAS变异的头颈部鳞状细胞癌患者从放疗加顺铂联合西妥昔单抗中显著获益,且KRAS变异与p16状态存在显著交互作用。
  • KRAS变异患者TGF-β1水平升高提示西妥昔单抗可能通过克服TGF-β1诱导的抗肿瘤免疫抑制发挥作用。

研究设计与样本

  • 研究为一项3期临床试验(NRG Oncology RTOG 0522)的二次分析,纳入891例晚期头颈部鳞状细胞癌患者,接受顺铂加放疗联合或不联合西妥昔单抗治疗。
  • 413例有可用样本的患者在CLIA认证实验室进行KRAS变异基因分型,376例有血浆样本用于TGF-β1检测。
  • 采用Cox比例风险模型估计风险比(HR)。

主要发现

  • 891例符合方案分析的患者中,786例男性(88.2%)、105例女性(11.2%),810例白人(90.9%)、81例非白人(9.1%)。
  • 413例接受KRAS变异检测的患者中,70例(16.9%)携带KRAS变异。
  • KRAS变异患者接受西妥昔单抗后第一年无进展生存期(PFS)的HR为0.31(95%CI 0.10-0.94,P=.04),1至2年总生存期(OS)的HR为0.19(95%CI 0.04-0.86,P=.03)。
  • 未接受西妥昔单抗治疗的患者中,KRAS变异与p16状态对PFS存在显著交互作用;p16阳性且KRAS变异的未接受西妥昔单抗患者PFS较无KRAS变异者差(HR 2.59,95%CI 0.91-7.33,P=.07)。
  • KRAS变异、p16状态与治疗对OS存在显著三重交互作用(P=.02):KRAS变异、接受西妥昔单抗且p16阳性者HR为0.22(95%CI 0.03-1.66);KRAS变异、接受西妥昔单抗且p16阴性者HR为1.43(95%CI 0.48-4.26);KRAS变异、未接受西妥昔单抗且p16阳性者HR为2.48(95%CI 0.64-9.65);KRAS变异、未接受西妥昔单抗且p16阴性者HR为0.61(95%CI 0.23-1.59)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is a significant need to find biomarkers of response to radiotherapy and cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and biomarkers that predict altered immunity, thereby enabling personalized treatment. OBJECTIVES: To examine whether the Kirsten rat sarcoma viral oncogene homolog (KRAS)-variant, a germline mutation in a microRNA-binding site in KRAS, is a predictive biomarker of cetuximab response and altered immunity in the setting of radiotherapy and cisplatin treatment and to evaluate the interaction of the KRAS-variant with p16 status and blood-based transforming growth factor β1 (TGF-β1). DESIGN, SETTING, AND PARTICIPANTS: A total of 891 patients with advanced HNSCC from a phase 3 trial of cisplatin plus radiotherapy with or without cetuximab (NRG Oncology RTOG 0522) were included in this study, and 413 patients with available samples were genotyped for the KRAS-variant. Genomic DNA was tested for the KRAS-variant in a CLIA-certified laboratory. Correlation of the KRAS-variant, p16 positivity, outcome, and TGF-β1 levels was evaluated. Hazard ratios (HRs) were estimated with the Cox proportional hazards model. MAIN OUTCOMES AND MEASURES: The correlation of KRAS-variant status with cetuximab response and outcome, p16 status, and plasma TGF-β1 levels was tested. RESULTS: Of 891 patients eligible for protocol analyses (786 male [88.2%], 105 [11.2%] female, 810 white [90.9%], 81 nonwhite [9.1%]), 413 had biological samples for KRAS-variant testing, and 376 had plasma samples for TGF-β1 measurement. Seventy patients (16.9%) had the KRAS-variant. Overall, for patients with the KRAS-variant, cetuximab improved both progression-free survival (PFS) for the first year (HR, 0.31; 95% CI, 0.10-0.94; P = .04) and overall survival (OS) in years 1 to 2 (HR, 0.19; 95% CI, 0.04-0.86; P = .03). There was a significant interaction of the KRAS-variant with p16 status for PFS in patients treated without cetuximab. The p16-positive patients with the KRAS-variant treated without cetuximab had worse PFS than patients without the KRAS-variant (HR, 2.59; 95% CI, 0.91-7.33; P = .07). There was a significant 3-way interaction among the KRAS-variant, p16 status, and treatment for OS (HR, for KRAS-variant, cetuximab and p16 positive, 0.22; 95% CI, 0.03-1.66; HR for KRAS-variant, cetuximab and p16 negative, 1.43; 95% CI, 0.48-4.26; HR for KRAS-variant, no cetuximab and p16 positive, 2.48; 95% CI, 0.64-9.65; and HR for KRAS-variant, no cetuximab and p16 negative, 0.61; 95% CI, 0.23-1.59; P = .02). Patients with the KRAS-variant had significantly elevated TGF-β1 plasma levels (median, 23 376.49 vs 18 476.52 pg/mL; P = .03) and worse treatment-related toxic effects. CONCLUSIONS AND RELEVANCE: Patients with the KRAS-variant with HNSCC significantly benefit from the addition of cetuximab to radiotherapy and cisplatin, and there is a significant interaction between the KRAS-variant and p16 status. Elevated TGF-β1 levels in patients with the KRAS-variant suggests that cetuximab may help these patients by overcoming TGF-β1-induced suppression of antitumor immunity. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00265941.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Weidhaas JB, Harris J, Schaue D, et al. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017. PMID: 28006059. doi:10.1001/jamaoncol.2016.5478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。